Menopause & Perimenopause

Menopause is the point at which a woman’s ovaries stop releasing eggs and stop producing significant amounts of estrogen and progesterone. It is defined retrospectively — once 12 consecutive months have passed without a menstrual period. In the United States and Europe, the average age of menopause is around 51 to 52.

The current European Society of Endocrinology guideline frames menopause as a spectrum rather than a single event. That spectrum includes the perimenopause (the transition leading up to the final menstrual period), the menopause itself, and the postmenopause that follows. Symptoms can begin years before the last period and can persist for years afterward.

Perimenopause is the transition phase. Ovarian function is declining but has not yet stopped — and the decline is not steady. Hormone levels swing unpredictably from one day to the next. A woman may have a normal hormone panel one week and a strikingly abnormal one the next, even when her symptoms are obvious and unrelenting.

Perimenopause typically begins in a woman’s 40s but can start earlier. It is often where the most disruptive symptoms appear — irregular bleeding, hot flashes, sleep disturbance, mood changes, brain fog, joint aches — and it is often the phase that gets misdiagnosed. Women are sent to a sleep specialist for insomnia, a psychiatrist for anxiety, a rheumatologist for joint pain, when in fact one underlying hormonal shift is driving all of it.

As Yale gynecologist Mary Jane Minkin has put it, menopause is the easy part — perimenopause is the tricky part. We agree, and we approach perimenopausal symptoms aggressively rather than telling women to “wait it out.”

For a woman over 45 with typical menopausal symptoms, the diagnosis is clinical. No blood test is required. FSH and estradiol fluctuate so much during this period that a single normal value does not rule out perimenopause and a single high value does not confirm it.

For a woman 40 to 45 with menstrual irregularity or vasomotor symptoms, biochemical testing can be considered if there is doubt about the diagnosis. For any woman under 40 with menstrual irregularity, unexplained subfertility, or hot flashes, evaluation is mandatory — premature ovarian insufficiency must be ruled out, because the long-term health implications are significant and treatment should not be delayed.

Premature ovarian insufficiency (POI) is the loss of ovarian function before age 40. It affects roughly 1 to 3% of women. Early menopause refers to menopause occurring between 40 and 45. Both are clinically important because the body is exposed to estrogen deficiency for many additional years compared to the average woman, and that deficiency drives measurable increases in cardiovascular disease, osteoporosis, cognitive decline, depression, and overall mortality.

The diagnosis of POI is made with one FSH greater than 25 IU/L in the right clinical context, or two such measurements at least four weeks apart when the picture is less clear. Once confirmed, additional workup is appropriate — including genetic testing where available, autoimmune screens, thyroid function, and bone densitometry.

Symptoms cluster across several body systems. Vasomotor symptoms — hot flashes and night sweats — are the most recognized, but they are far from the whole story. Most women experience symptoms in multiple domains, and the symptoms often interact: poor sleep worsens mood, mood worsens cognition, and so on.

Vasomotor symptoms — hot flashes and night sweats — last on average about 7 years. In about 1 in 10 women they last 12 years or more. They are usually most intense in the year or two after the final menstrual period.

Genitourinary symptoms (vaginal dryness, painful sex, urinary symptoms) follow a different pattern — they tend to begin later and to persist or progress over time rather than resolve. They are caused by ongoing estrogen deficiency in the vaginal and urinary tissues, and they generally do not improve without treatment.

Estrogen has receptors in essentially every tissue of the body. When estrogen declines, the consequences extend well beyond hot flashes and mood. The four areas where the long-term impact is most clinically significant are the bones, the cardiovascular system, the brain, and the urogenital tract.

Estrogen is the most important hormonal regulator of bone remodeling in women. With its loss, bone resorption outpaces bone formation, and bone mineral density falls — most rapidly in the first several years after the final menstrual period. The result is a measurable increase in fracture risk, particularly at the spine and hip.

The protective effect of estrogen on the skeleton has been confirmed across large randomized trials. In the Women’s Health Initiative, hormone therapy reduced hip fractures by roughly a third compared with placebo. We screen high-risk patients with bone density testing and discuss preventive options proactively — not only after a fracture has already occurred.

Yes, and the change is mediated in part by the loss of estrogen. Before menopause, women have substantially lower rates of coronary disease than men of the same age. That advantage narrows during the menopause transition and largely disappears in the years that follow. Women who go through menopause early — and especially women with premature ovarian insufficiency — face the highest risk.

Cardiovascular disease is the leading cause of death in women in the United States. The menopause transition is itself recognized as a window of increased cardiovascular risk by the American Heart Association, and is a critical time to address the modifiable risks: blood pressure, lipids, blood glucose, weight, physical activity, and tobacco use.

The “brain fog” that many women describe in perimenopause is real and well-documented. Verbal memory in particular dips during the transition. For most women, cognitive performance returns toward baseline in the years after menopause.

Whether menopause raises long-term risk for Alzheimer’s disease is an active area of research. Two-thirds of Alzheimer’s patients are women, which is not fully explained by longevity alone. Estrogen has known neuroprotective effects in the laboratory. The clinical data on hormone therapy and dementia risk are mixed and depend heavily on age at initiation — and we do not currently use hormone therapy to prevent or treat dementia. But we do take cognitive symptoms seriously and address the modifiable contributors: sleep, mood, vasomotor symptoms, vascular risk factors, and thyroid function.

Our position is straightforward: menopause is an endocrine event, and it deserves endocrine care. We approach it the way we approach any other hormonal deficiency — with attention to the individual patient, the evidence, the risks, and the benefits, and a willingness to actually treat.

Sleep disturbance, mood symptoms, and cognitive complaints in perimenopause and menopause are often downstream of hormonal change, even when they don’t feel that way. Treating the underlying hormonal shift often resolves several of these complaints at once — which is why a systemic approach beats symptom-by-symptom treatment.

This is one of the most misunderstood questions in menopause medicine. The short answer is: we do not start hormone therapy purely to prevent cardiovascular disease. But the long-running concern that hormone therapy causes heart disease has been substantially walked back, and for many women hormone therapy is cardiovascularly safe.

Age-stratified analyses of the Women’s Health Initiative and other studies show that women who begin hormone therapy within 10 years of menopause or before age 60 do not have an increased risk of heart disease, and may have a modest reduction in coronary mortality and all-cause mortality. The increased cardiovascular risk seen in the original WHI publication was driven largely by older women — average age 63, an average of 10 years past menopause — who would not be considered ideal candidates today.

Practical implications: cardiovascular risk factors (blood pressure, lipids, glucose, weight) should be optimized before starting hormone therapy. In women with elevated cardiovascular risk, transdermal estrogen is preferred over oral. Hormone therapy is not used to prevent stroke, and a personal history of cardiovascular disease changes the calculus considerably.

Yes, in most cases — provided these conditions are well-controlled. Well-controlled diabetes is not a contraindication to hormone therapy. In fact, hormone therapy is associated with a roughly 30% reduction in the incidence of new type 2 diabetes and modest improvements in HbA1c and fasting glucose in women already diagnosed. Transdermal estrogen is preferred in these patients.

Well-controlled hypertension is also not a contraindication. Hormone therapy should not be initiated in the setting of uncontrolled hypertension, but once blood pressure is at goal, transdermal estrogen has a neutral effect on blood pressure and is safe.

Estrogen suppresses bone resorption. Replacing it after menopause prevents the rapid bone loss that follows the final menstrual period and reduces the risk of osteoporotic fracture. The Women’s Health Initiative — the largest randomized trial of hormone therapy ever conducted — showed roughly a 33% reduction in hip fracture and 35% reduction in vertebral fracture in women on combined estrogen-progestin therapy, and similar reductions with estrogen alone.

For women within 10 years of menopause and under 60 with bothersome symptoms, fracture protection is a meaningful additional benefit. For women without symptoms but with risk factors for osteoporosis, hormone therapy can be considered for bone protection if other antiresorptive options are not preferred.

Lifestyle measures matter too: weight-bearing exercise, adequate calcium and vitamin D, fall prevention, and avoidance of tobacco and excessive alcohol.

The honest answer is more nuanced than either the original 2002 headlines or the current “all clear” social media take. The risk depends on the type of hormone therapy, the duration of use, the formulation of progestogen, and the woman’s baseline risk.

For context: the absolute increase in breast cancer risk with combined hormone therapy in the WHI was roughly 9 additional cases per 10,000 women per year. We discuss these numbers concretely with every patient before starting therapy. Personal and family history matter, and we adjust accordingly.

Systemic hormone therapy is not recommended in women with a history of breast cancer. Non-hormonal options for vasomotor symptoms, mood, and sleep should be tried first. For genitourinary symptoms — vaginal dryness, painful intercourse, urinary symptoms — non-hormonal lubricants and moisturizers are first-line. When these are insufficient, low-dose vaginal estrogen can be considered, and recent meta-analyses have not shown an increase in recurrence with this approach. Any such decision should be made jointly with the patient’s oncologist.

The genitourinary syndrome of menopause affects roughly half of postmenopausal women and, unlike hot flashes, it does not improve on its own. It includes vaginal dryness, burning, itching, painful intercourse, urinary urgency, and recurrent urinary tract infections. It responds extremely well to treatment, and it is dramatically undertreated.

In 2002, the Women’s Health Initiative reported that combined estrogen-progestin therapy increased the risk of breast cancer, heart disease, and stroke. Use of hormone therapy fell by roughly half within six months. An entire generation of women — and their physicians — turned away from it.

What followed in the years after has been less widely publicized: re-analyses of the same data exposed important limitations. The average woman in WHI was 63 years old and a full decade past menopause — already at meaningful baseline cardiovascular risk. The trial used one regimen — daily oral conjugated equine estrogens combined with medroxyprogesterone acetate — that has largely been replaced by transdermal estradiol and micronized progesterone in modern practice. When the WHI data are re-examined by age, women who started hormone therapy within 10 years of menopause did not show increased cardiovascular risk and showed a reduction in all-cause mortality.

The current evidence has settled into a more nuanced picture: hormone therapy is the most effective treatment for vasomotor symptoms, prevents bone loss, treats the genitourinary syndrome, and — when started in the right window in the right patient — is safe. We think withholding it from a woman who would benefit is a bigger mistake than offering it.

The “right” hormone therapy is the one matched to the individual woman — her uterine status, her cardiovascular risk, her preference, and any contraindications. We have many options.

It often does. Oral estrogen passes through the liver before reaching the bloodstream, which raises clotting factors, triglycerides, and inflammatory markers. Transdermal estrogen bypasses this first-pass effect and has a more favorable cardiovascular and venous thrombosis profile.

We usually prefer transdermal estrogen when any of the following are present: a personal or family history of venous thromboembolism, hypertension, controlled diabetes, obesity, hypertriglyceridemia, migraine with aura, or simply a desire to minimize cardiovascular risk. For a woman in her early 50s with no cardiovascular risk factors, oral and transdermal are both reasonable, and patient preference matters.

FDA-approved estradiol and micronized progesterone are already bioidentical — chemically identical to the hormones the ovary produces. They have undergone testing for safety, purity, and consistent dosing. We use them routinely.

What is sometimes marketed as “bioidentical hormone therapy” — custom-compounded combinations of estradiol, estrone, estriol, DHEA, testosterone, and progesterone, often delivered as pellets, troches, or implants — is a different category. These products are not FDA-regulated, lack rigorous safety and pharmacokinetic data, and supraphysiologic dosing through pellets in particular has been associated with adverse effects. We recommend compounded preparations only when an FDA-approved option cannot meet a documented clinical need (such as a true allergy to a non-active ingredient).

Most women with bothersome menopausal symptoms who initiate therapy within 10 years of menopause or before age 60 are good candidates. The risk-benefit profile is most favorable in this window — sometimes called the “timing hypothesis.”

Particularly strong indications include:

Systemic hormone therapy is generally not appropriate in women with:

• A history of breast cancer (vaginal estrogen may still be considered with oncology input)
• Active or recent venous thromboembolism, unless after individualized assessment with transdermal-only preparations
• Active or recent coronary artery disease, stroke, or transient ischemic attack
• Active liver disease
• Unexplained vaginal bleeding before evaluation
• Untreated endometrial hyperplasia or cancer
• Pregnancy

For many of these patients, non-hormonal therapies — SSRIs/SNRIs, gabapentin, NK3-receptor antagonists, cognitive behavioral therapy — can still meaningfully reduce symptoms. And for genitourinary symptoms specifically, low-dose vaginal estrogen is often safe even in many women who cannot use systemic therapy.

There is no arbitrary cutoff. The decision to continue is made together — based on whether symptoms are still present, whether the benefit-risk balance still favors treatment, and what the patient prefers. Some women take hormone therapy for a few years to bridge through the worst of the transition. Others continue longer for ongoing symptom relief, bone protection, or quality of life.

For women over 60, the conversation shifts somewhat — age itself raises the cardiovascular and breast cancer risks that hormone therapy can compound. We do not stop therapy reflexively at 60 or 65. We re-evaluate, often shift to a non-oral route at the lowest effective dose, and continue if benefit clearly exceeds risk.

For women with premature ovarian insufficiency, hormone replacement should generally continue at least until the average age of natural menopause — around 51 — and then be reassessed.

We re-evaluate three months after starting therapy to confirm symptoms are controlled and the regimen is well tolerated. If symptoms persist or side effects develop, we adjust the dose, route, or progestogen — there are many options, and finding the right fit often takes one or two iterations.

After that, follow-up is typically annual. We check blood pressure, weight, and changes in personal or family history. We continue routine breast cancer screening per national guidelines. We do not routinely check estradiol or FSH levels in women on hormone therapy for symptom control; symptoms are the better guide.

Roughly 1.3 million American women reach menopause every year. About a quarter experience symptoms severe enough to disrupt their lives. Many of them have been told that what they are experiencing is “normal aging,” that hormone therapy is dangerous, or that they should simply wait it out.

Modern menopause care is none of these things. It is rigorous, individualized, and effective. We treat menopause as the endocrine event it is — and we do not ask women to suffer through symptoms that we have safe, effective tools to address.